Paperpal Prime Logo

Therapeutic Advances in Respiratory Disease : Impact Factor & More

eISSN: 1753-4666pISSN: 1753-4658
JournalOpen Access

Key Metrics

CiteScore
6.8
H-Index
46
Impact Factor
< 5
SJR
Q1Pharmacology (medical)
SNIP
1.42
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Respiratory Disease

Therapeutic Advances in Respiratory Disease Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time15
Editorial Review ProcessOpen peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2007
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 15
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessOpen peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Respiratory Disease ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Respiratory Disease

Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions
  • 1 Aug 2026
  • Therapeutic Advances in Respiratory Disease
Surgical management of refractory massive hemoptysis from pulmonary artery pseudoaneurysm due to Streptococcus constellatus: a rare case report and literature review
  • 29 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Rural and urban environmental exposures and the risk of progressive pulmonary fibrosis
  • 28 Jul 2026
  • Therapeutic Advances in Respiratory Disease
The prevalence and unique clinical features of CPFE among patients with connective tissue disease\u2013associated interstitial lung disease: a retrospective, real-world study
  • 27 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Association between organophosphate insecticide metabolites and lung function in U.S. adults: NHANES 2011\u20132012
  • 27 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment
  • 25 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions
  • 1 Aug 2026
  • Therapeutic Advances in Respiratory Disease
Surgical management of refractory massive hemoptysis from pulmonary artery pseudoaneurysm due to Streptococcus constellatus: a rare case report and literature review
  • 29 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Rural and urban environmental exposures and the risk of progressive pulmonary fibrosis
  • 28 Jul 2026
  • Therapeutic Advances in Respiratory Disease
The prevalence and unique clinical features of CPFE among patients with connective tissue disease\u2013associated interstitial lung disease: a retrospective, real-world study
  • 27 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Association between organophosphate insecticide metabolites and lung function in U.S. adults: NHANES 2011\u20132012
  • 27 Jul 2026
  • Therapeutic Advances in Respiratory Disease
Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment
  • 25 Jul 2026
  • Therapeutic Advances in Respiratory Disease

FAQs on Therapeutic Advances in Respiratory Disease